Daxor Focuses on Long-term Growth Through Strategic Initiatives

Oak Ridge, TN, Sept. 01, 2026 /CourierPR/ -- Daxor Corporation, a global leader in blood volume measurement technology, has delivered its mid-year corporate and financial update through a shareholder letter from CEO and President Michael Feldschuh. The letter underscores the company's commitment to laying the groundwork for future growth rather than focusing on immediate profits.

Building the Foundation for Growth

“Everything we have accomplished to date has been about building the launch pad, not the destination,” Feldschuh wrote, echoing Jeff Bezos' philosophy. In the first half of 2026, Daxor focused on laying the groundwork to enable aggressive growth in the second half and beyond. Key initiatives included a $9 million capital raise in January, the acquisition of Isotex Diagnostics, and the expansion of its sales and clinical support teams.

Strengthening the Commercial Team

The capital raise allowed Daxor to strengthen its commercial capabilities. The company reported a 16% increase in unaudited kit sales in the first half of 2026 compared to the same period last year. This growth is attributed to the legacy commercial structure the company carried into the year, which laid the groundwork for expansion. In April, Daxor appointed Annette Plishka as the new Senior Vice President of Sales, and has been actively hiring and training additional sales managers to expand its field presence.

Expanding Commercial Footprint

Daxor's dual-solution strategy, combining on-site BVA analyzers with its CLIA-certified, zero-capital ezBVA Lab send-out service, drove new account activity during the period. Notable new accounts include a new outpatient BVA program in Southern Middle Tennessee and a high-volume cardiology center in Southwest Ohio. The company also maintained an active presence at industry conferences, including SCCM, ACC.26, MedAxiom CV Transforum, and the iAccess Alpha investor conference.

Next-Generation BVA System

Demand for Daxor's next-generation BVA system is robust, with indications of interest from more than fifteen hospitals and practices. The company expects to place these units over the next several quarters as it ramps up production and installation capacity. Each new placement is expected to drive incremental kit sales demand and open new points of care, extending the reach of precision blood volume measurement to a broader population.

Financial Position

As of June 30, 2026, Daxor's net assets stood at $51,832,130, an increase of $5,944,864 from December 31, 2025. The financial position is clean, with no outstanding debt, and the capital structure is straightforward, consisting of 5,838,224 shares of common stock. The company used the January capital raise to retire $1,169,913 of short-term debt and invest in the manufacturing capacity and inventory needed for the next-generation platform.

Corporate Structure and Strategic Realignment

Daxor announced its intention to transition primary regulatory reporting from the Investment Company Act of 1940 to the Securities Exchange Act of 1934, recognizing its operation as a medical diagnostics and technology company. The company is also focusing its efforts entirely on the Blood Volume Analysis business and the radiopharmaceutical manufacturing capability it is building out.

Intellectual Property and Research & Development

On June 2, 2026, the USPTO issued U.S. Patent No. 12,635,917 B2, “Remote Blood Volume Monitor,” extending Daxor’s intellectual property protection beyond point-of-care testing into continuous, wearable-sensor-based monitoring. This patent supports the company's mission to provide precise blood volume measurements, which are critical for improved patient outcomes and reduced healthcare costs.

Health-Economic Impact

Daxor's precision blood volume measurement technology addresses the silent crisis in healthcare, where clinicians rely on indirect proxies to estimate patient volume status. This technology provides direct, precise measurements, improving outcomes and reducing hospital readmissions, thereby lowering the overall burden on healthcare systems.

In summary, Daxor Corporation is well-positioned for aggressive growth in the second half of the year and beyond, with a strong financial foundation and a robust commercial strategy in place.